Hepatitis B
Stories
-
FDA releases final guidance on reducing transfusion-transmitted Hepatitis B virus
FDA announces availability of the final guidance titled "Recommendations for Reducing the Risk of Transfusion-Transmitted Hepatitis B Virus" on November 3, 2026. The guidance supersedes several earlier documents and applies to the collection of Whole Blood and blood components, including Source Plasma.
-
FDA approves Hibsago for certain adults with chronic hepatitis B
Across pooled Phase 3 trials, 19% of Hibsago recipients met GSK's functional-cure measure 24 weeks after stopping treatment. FDA approval adds Hibsago with existing antiviral therapy for eligible adults without cirrhosis.
-
PT Bio Farma registers Phase 3 trial of in-house recombinant Hepatitis B vaccine at birth dose
This study was first posted on ClinicalTrials.gov on October 2, 2026. The trial plans to enroll 270 participants and has a planned start date of October 2026 with a planned primary completion date of February 2027.